Medicine company Eli Lilly and Company (NYSE: LLY) revealed on Wednesday that it has achieved positive 48-week Phase 2b results for EloraTZP, its investigational combination of eloralintide and tirzepatide, showing greater weight loss and A1C reduction than tirzepatide 15 mg in adults with obesity or overweight and type 2 diabetes.
Participants receiving the highest EloraTZP combination lost an average 23.3% of body weight, or 54.1 lbs, compared with 14.8%, or 34.4 lbs, with tirzepatide 15 mg. Average A1C reductions were 2.9% and 2.4%, respectively.
The most common adverse events were generally mild to moderate gastrointestinal effects, occurring mainly during dose escalation. Lilly plans to initiate Phase 3 trials of an EloraTZP co-formulation by the end of 2026 using an optimised escalation schedule.
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
Aroa Biosurgery reports significantly improved healing of diabetic foot ulcers in Symphony trial
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
Revvity launches IVDR-certified solution for early detection of type 1 diabetes
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Foventa makes key CMO and CFO appointments
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Nippon Kinzoku begins mass production of ultra-thin stainless steel for insulin needles
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321